% | $
Quotes you view appear here for quick access.

Eli Lilly and Company Message Board

  • bluecheese4u bluecheese4u Oct 24, 2012 7:15 AM Flag

    Lilly Reports Third-Quarter 2012 Results

    Lilly Reports Third-Quarter 2012 Results

    INDIANAPOLIS, Oct. 24, 2012 /PRNewswire/ --

    •Worldwide revenue declined 11 percent to $5.443 billion, driven by Zyprexa patent expirations.
    •Cymbalta revenue increased 16 percent due to continued growth in both the U.S. and international markets.
    •Third-quarter earnings per share were $1.18 (reported), or $0.79 (non-GAAP, when excluding income from Amylin payment and asset impairment and restructuring charge).
    •Data read-outs provided a better understanding of several potential new medicines in Lilly's clinical pipeline.
    •2012 non-GAAP EPS guidance reconfirmed to be in the range of $3.30 - $3.40, while reported EPS guidance range revised to $3.68 - $3.78.

    Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2012.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
83.74-0.14(-0.17%)Nov 25 4:00 PMEST